Optics tissue-therapy company NuVision Biotherapies has named Joanna Underhill as its new non-executive director.
Joanna will provide an integral voice at board level, working closely with NuVision’s commercial teams to strengthen the company’s sales infrastructure, sharpen its pipeline focus, and support its commercial strategy. She will play a key role in market validation as NuVision expands into community and private optical care in the UK, and continues to grow its international footprint.
Joanna brings a strong commercial background across the UK and international markets, including the Gulf region which is a key area of focus for NuVision. She is currently the General Manager for the UK and Ireland at Teoxane, appointed to the role in October 2025. She previously served as General Manager for Allergan Aesthetics in the Gulf States, where she led a $50M business to sustained growth and operational excellence. Prior experience includes the role of Sales Director for the UK and Ireland arm of Allergan Aesthetics (an AbbVie company), alongside significant tenure at Galderma, Merz Aesthetics, Astellas Pharma, and the Swiss healthcare company Roche.
The appointment follows Mark Treherne stepping down as non-executive director, a role he held for 18 months after serving over five years as NuVision’s chair. This change reflects a deliberate shift in board composition as NuVision moves from an R&D focus into its next phase of commercialisation which was central to the company’s most recent investment round. The board sought a non-executive director with a proven track record in sales-led roles to support this transition.
Commenting on her appointment, Joanna said: “NuVision is at a genuinely exciting period. The science behind the product is exceptional and I’ve been struck by the quality of the team and the opportunities ahead. I am looking forward to bringing my commercial experience to the board and helping NuVision realise its full potential.”
Roger Teasdale, Chairman at NuVision, added: “Jo’s appointment is a significant moment for us. Her depth of experience in building and scaling commercial operations makes her ideally placed to support us as we enter this new chapter. We are also deeply grateful to Mark Treherne for his contribution to NuVision, firstly as chair and latterly as non-executive director. His guidance during our R&D phase has been crucial in transitioning us to this point, and we wish him well.”
For more information about NuVision, please visit www.nu-vision.co.uk.
Ends
Notes to Editors
All enquiries should be directed to Jenny Marston PR (07957 630 688; jennymarstonpr@gmail.com).
About NuVision Biotherapies
Located in Nottingham, NuVision Biotherapies is a tissue-therapy company that is based on 15 years of translational research at the University of Nottingham. The business was founded in 2015 with investment from Mercia Fund Management.
NuVision develops and provides a selection of products that pioneer therapies in ophthalmology. The Tereo Process is an established, dual patented manufacturing process that enables the scalable production of amniotic membrane processing.
Omnigen is NuVision’s ocular-specific Tereo processed amniotic membrane product, originating from the innermost layer of the placental sac that protects the foetus during pregnancy. Omnigen is processed using Tereo, therefore the product retains its natural tissue quality to preserve its barrier function and structural integrity. Omnigen can be directly applied to the ocular surface and therefore no preparation time is required prior to use. Omnigen is currently available in 140 UK hospitals, 30 UK private hospitals and seven countries.
NuVision also provides OmniLenz, a specialised bandage for the in-office application of Omnigen in a four to six minute procedure. The product is currently available in three sizes, allowing healthcare professionals to make a clinical decision on the version of the treatment they offer. The combination of Omnigen and OmniLenz accounts for approximately ~80% of all unit sales.